Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between genetically proxied lipid-lowering drug targets, lipid traits, and amyotrophic lateral sclerosis: a mendelian randomization study.

Acta neurologica Belgica - 1 Apr 2024

Yan Zhaoqi, Xu Yifeng, Li Keke, Liu Liangji

Abstract excerpt

BACKGROUND: The use of circulating lipid traits as biomarkers to predict the risk of amyotrophic lateral sclerosis (ALS) is currently controversial, and the evidence-based medical evidence for the use of lipid-lowering agents, especially statins, on ALS risk remains insufficient. Our aim was to apply a Mendelian randomization (MR) approach to assess the causal impact of lipid-lowering agents and circulating lipid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis
Share to Amyotrophic Lateral Sclerosis Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apolipoproteins B

Share to Cholesterol, LDL

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Mendelian Randomization Analysis

Share to Neurogenetic and Muscular Disorders Research

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 37889424
DOI: 10.1007/s13760-023-02393-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between genetically proxied lipid-lowering drug targets, lipid traits, and amyotrophic lateral sclerosis: a mendelian randomization study.PMID 37889424Read ↗

Mendelian Randomization Analysis Reveals Statins Potentially Increase Amyotrophic Lateral Sclerosis Risk Independent of Peripheral Cholesterol-Lowering EffectsSemantic proximity Read ↗

Lipids and amyotrophic lateral sclerosis: A two-sample Mendelian randomization study.Semantic proximity Read ↗

Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study.Semantic proximity Read ↗

Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization.Semantic proximity Read ↗

Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization studySemantic proximity Read ↗

Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis.Semantic proximity Read ↗

Genetic insights of lipid metabolism and lipid-lowering drugs with Lewy body dementia risk: Evidence from Mendelian randomization.Semantic proximity Read ↗

Causal relationship between cholesterol-lowering therapy and Alzheimer Disease: evidence from genetic correlation and Mendelian randomization studySemantic proximity Read ↗

A review of Mendelian randomization in amyotrophic lateral sclerosisSemantic proximity Read ↗

Polygenic Link Between Blood Lipids And Amyotrophic Lateral SclerosisSemantic proximity Read ↗

Atorvastatin, simvastatin, rosuvastatin and Amyotrophic lateral sclerosis establishing cause and effectSemantic proximity Read ↗

Polygenic link between blood lipids and amyotrophic lateral sclerosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.